Safety of avoiding systemic corticosteroid administration for grade II acute graft-versus-host disease limited to the skin
- 30 September 2017
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 97 (1) , 169-179
Abstract
We hypothesized that systemic corticosteroid administration would be safely avoided not only in grade I acute graft-versus-host disease (GVHD) but also in selected patients with grade II acute GVHD limited to the skin (grade IIs GVHD). We retrospectively evaluated risk factors for subsequent GVHD progression, defined as the involvement of other organs or progression to grade III to IV GVHD, in 50 patients with acute GVHD of grade IIs at its onset. Sixteen patients received systemic corticosteroid administration before GVHD progression. The cumulative incidence of GVHD progression at 28 days from the onset of grade IIs GVHD was 24%. Twenty-five patients did not require systemic corticosteroid administration throughout the entire episode of acute GVHD. Systemic corticosteroid administration before GVHD progression did not affect GVHD progression, chronic GVHD, or non-relapse mortality. Early onset (less than 26 days from transplantation) of grade IIs GVHD was identified as the only statistically significant risk factor for GVHD progression (hazard ratio 6.73, 95% confidence interval 1.5–31.1, P = 0.01). In conclusion, avoiding systemic corticosteroid administration for selected patients with grade IIs GVHD before GVHD progression did not compromise the transplantation outcomes. Patients with early-onset grade IIs GVHD were at high risk for GVHD progression.Keywords
This publication has 21 references indexed in Scilit:
- Manifestations and Treatment of Acute Graft‐versus‐Host Disease2015
- Diagnosis and management of acute graft‐versus‐host diseaseBritish Journal of Haematology, 2012
- How I treat refractory acute GVHDBlood, 2007
- Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivationBlood, 2003
- Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioningBlood, 2003
- Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factorsBlood, 2002
- Risk Factors for Acute Graft-Versus-Host Disease After Allogeneic Blood Stem Cell TransplantationBlood, 1999
- Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease preventionBlood, 1994
- A retrospective analysis of therapy for acute graft-versus-host disease: initial treatmentBlood, 1990
- Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapyBlood, 1990